Conatus Pharmaceuticals' (CNAT) Price Target Raised to $26 at SunTrust
Tweet
Share
E-mail
Get Alerts CNAT Hot Sheet
Price: $0.56 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
SunTrust Robinson Humphrey maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT) and raised its price target to $26.00 (from $17.00).
For an analyst ratings summary and ratings history on Conatus Pharmaceuticals click here. For more ratings news on Conatus Pharmaceuticals click here.
Shares of Conatus Pharmaceuticals closed at $1.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Bukit Asam Tbk PT (PTBA:IJ) to Underweight
- Linde (LIN) PT Lowered to $563 at Bernstein SocGen Group
- Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) PT Raised to IDR2,860 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, Momentum MoversRelated Entities
SunTrust Robinson HumphreySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
